9/6/2019
International Celiac Disease Symposium Presentations – Marilyn’s Message September 2019
CEO Marilyn G. Geller speaks at the 18th International Celiac Disease Symposium (ICDS).
Continue ReadingFeatured News
Tag: updates
9/6/2019
ActoBio Announces Phase 1b/2a Trial for ActoBiotics® AG017
ActoBio announces FDA has given permission to an Investigational New Drug (IND) application for Actobiotics® AG017, a therapeutic candidate for celiac disease.
Continue ReadingRecent Posts
- Exploring the Intersection of Nutrition Science and Policy: Highlights from the NIH-FDA Workshop
- Challenges Persist for Students with Celiac Disease in Free School Meal Programs
- Please Join Us for the Teal Pumpkin Project 2024!
- Why Aren't Most Rice Krispy Treats Gluten-Free?
Search the archive
Categories
- Advocacy News
- Celiac Disease in the News
- Clinical Trials
- Eat! Gluten-Free
- Featured
- Foundation Press
- iCureCeliac
- Marilyn’s Message
- Monthly eNewsletter
- Patient Profile Advocacy Series
- Research News
- Research Press
- Trending Topics
Marilyn's Message
9/26/2024
Read more2024 International Celiac Disease Symposium Recap
Last month, the Celiac Disease Foundation had the privilege of sponsoring the 2024 International Celiac Disease Symposium in Sheffield, UK. As the first patient advocate invited to chair and present on a scientific panel, CEO Marilyn Geller co-chaired the End Points in Clinical Trials session with Dr. Francisco Leon, CEO...